Original paper
Required efficacy for novel therapies in BCG‐unresponsive non‐muscle invasive bladder cancer: Do current recommendations really reflect clinically meaningful outcomes?
Abstract
Background Single‐arm trials are currently an accepted study design to investigate the efficacy of novel therapies (NT) in non‐muscle invasive bladder cancer (NMIBC) unresponsive to intravesical Bacillus Calmette‐Guérin (BCG) immunotherapy as randomized controlled trials are either unfeasible (comparator: early radical cystectomy; ERC), or unethical (comparator: placebo). To guide the design of such single‐arm trials, expert groups published...
Paper Details
Title
Required efficacy for novel therapies in BCG‐unresponsive non‐muscle invasive bladder cancer: Do current recommendations really reflect clinically meaningful outcomes?
Published Date
Mar 12, 2020
Journal
Volume
9
Issue
10
Pages
3287 - 3296
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History